Douglas Evan Godshall Sells 30,000 Shares of ShockWave Medical, Inc. (NASDAQ:SWAV) Stock

ShockWave Medical, Inc. (NASDAQ:SWAVGet Rating) CEO Douglas Evan Godshall sold 30,000 shares of the business’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $240.81, for a total value of $7,224,300.00. Following the completion of the sale, the chief executive officer now directly owns 82,926 shares in the company, valued at approximately $19,969,410.06. The sale was disclosed in a legal filing with the SEC, which is available through this link.

ShockWave Medical Price Performance

NASDAQ SWAV opened at $248.01 on Friday. The company has a quick ratio of 6.02, a current ratio of 7.29 and a debt-to-equity ratio of 0.04. The company has a market cap of $8.96 billion, a PE ratio of 106.44 and a beta of 1.03. ShockWave Medical, Inc. has a 52 week low of $113.36 and a 52 week high of $320.54. The firm’s 50-day simple moving average is $273.71 and its two-hundred day simple moving average is $231.75.

Institutional Trading of ShockWave Medical

Hedge funds and other institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its stake in ShockWave Medical by 24.3% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,214,678 shares of the company’s stock valued at $614,550,000 after buying an additional 627,712 shares in the last quarter. State Street Corp boosted its holdings in shares of ShockWave Medical by 56.5% in the second quarter. State Street Corp now owns 1,125,735 shares of the company’s stock worth $215,207,000 after acquiring an additional 406,327 shares during the period. Renaissance Technologies LLC grew its position in shares of ShockWave Medical by 647.0% in the third quarter. Renaissance Technologies LLC now owns 322,700 shares of the company’s stock valued at $89,733,000 after purchasing an additional 279,500 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of ShockWave Medical by 2,286.1% during the 2nd quarter. Principal Financial Group Inc. now owns 243,188 shares of the company’s stock valued at $46,490,000 after purchasing an additional 232,996 shares during the period. Finally, Macquarie Group Ltd. lifted its holdings in ShockWave Medical by 26.3% during the 2nd quarter. Macquarie Group Ltd. now owns 1,117,137 shares of the company’s stock worth $213,563,000 after purchasing an additional 232,570 shares in the last quarter. Institutional investors own 95.40% of the company’s stock.

Analysts Set New Price Targets

SWAV has been the subject of a number of analyst reports. Wells Fargo & Company lifted their price objective on ShockWave Medical from $255.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 8th. Morgan Stanley raised their price objective on ShockWave Medical from $255.00 to $290.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 11th. Bank of America lifted their price objective on ShockWave Medical from $260.00 to $310.00 in a report on Monday, November 7th. Canaccord Genuity Group upped their price target on shares of ShockWave Medical from $232.00 to $256.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. Finally, Piper Sandler lifted their price target on ShockWave Medical from $278.00 to $338.00 and gave the company an “overweight” rating in a research note on Monday, August 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $263.00.

About ShockWave Medical

(Get Rating)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Further Reading

Insider Buying and Selling by Quarter for ShockWave Medical (NASDAQ:SWAV)

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.